CytoDyn Inc.
CYDY
$0.25
-$0.01-2.00%
OTC PK
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.34% | -32.84% | -19.62% | -9.64% | -27.81% |
| Depreciation & Amortization | 50.00% | -- | -145.71% | -135.00% | -111.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.80% | -15.14% | 11.10% | 3.77% | -54.92% |
| Operating Income | -10.80% | 15.14% | -11.10% | -3.77% | 54.92% |
| Income Before Tax | -10.39% | 107.51% | 86.29% | 73.35% | 72.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.39% | 107.51% | 86.29% | 73.35% | 72.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.39% | 107.51% | 86.29% | 73.35% | 72.95% |
| EBIT | -10.80% | 15.14% | -11.10% | -3.77% | 54.92% |
| EBITDA | -10.86% | 15.10% | -11.24% | -3.91% | 54.87% |
| EPS Basic | 21.55% | 105.88% | 84.63% | 72.22% | 72.77% |
| Normalized Basic EPS | 34.34% | 44.79% | 47.37% | 48.62% | 62.86% |
| EPS Diluted | 12.61% | 99.81% | 83.57% | 72.54% | 72.99% |
| Normalized Diluted EPS | 33.94% | 45.31% | 47.77% | 48.97% | 63.09% |
| Average Basic Shares Outstanding | 20.83% | 24.38% | 21.71% | 19.96% | 17.45% |
| Average Diluted Shares Outstanding | 18.99% | 26.01% | 23.39% | 21.71% | 19.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |